FOXC2 Monoklonaler Antikörper

FOXC2 Monoklonal Antikörper für IHC, WB, ELISA

Wirt / Isotyp

Maus / IgG2b

Getestete Reaktivität

Hausschwein, human, Ratte

Anwendung

WB, IHC, IF, ELISA

Konjugation

Unkonjugiert

Publikationen

1

CloneNo.

3E3E1

Kat-Nr. : 68384-1-Ig

Synonyme

FKHL14, Forkhead box protein C2, FOXC2, LD, Mesenchyme fork head protein 1, MFH 1, MFH 1 protein, MFH1, Transcription factor FKH 14

---

Galerie der Validierungsdaten

• 

  WB analysis of hTERT-RPE1 using 68384-1-Ig

  hTERT-RPE1 cells were subjected to SDS PAGE followed by western blot with 68384-1-Ig (FOXC2 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 68384-1-Ig

  Various lysates were subjected to SDS PAGE followed by western blot with 68384-1-Ig (FOXC2 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human breast cancer using 68384-1-Ig

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 68384-1-Ig (FOXC2 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 68384-1-Ig

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 68384-1-Ig (FOXC2 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: hTERT-RPE1-Zellen, Hausschwein-Fettgewebe, Rattenherzgewebe, Rattennierengewebe, U-87 MG-Zellen
• Erfolgreiche Detektion in IHC: humanes Mammakarzinomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:6000
• Immunhistochemie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• IF: See 1 publications below

Produktinformation

68384-1-Ig bindet in WB, IHC, IF, ELISA FOXC2 und zeigt Reaktivität mit Hausschwein, human, Ratten

• Getestete Reaktivität: Hausschwein, human, Ratte
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Maus / IgG2b
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: FOXC2 fusion protein Ag19378
• Vollständiger Name: forkhead box C2 (MFH-1, mesenchyme forkhead 1)
• Berechnetes Molekulargewicht: 501 aa, 54 kDa
• Beobachtetes Molekulargewicht: 56 kDa
• GenBank-Zugangsnummer: BC113437
• Gene symbol: FOXC2
• Gene ID (NCBI): 2303
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Forkhead box protein C2 (FOXC2) also known as forkhead-related protein FKHL14 (FKHL14), transcription factor FKH-14, or mesenchyme fork head protein 1 (MFH1) is a protein that in humans is encoded by the FOXC2 gene. FOXC2 is a member of the fork head box (FOX) family of transcription factors. FOX transcription factors are expressed during development and are associated with a number of cellular and developmental differentiation processes. FOXC2 is required during early development of the kidneys, including differentiation of podocytes and maturation of the glomerular basement membrane. It is also involved in the early development of the heart. FOXC2 is also involved in cancer metastases. In particular, expression of FOXC2 is induced when epithelial cells undergo an epithelial-mesenchymal transition (EMT) and become mesenchymal looking cells. (PMID: 8674414 9169153 19935708)

Publikationen

Species	Application	Title
human	IF	Cell Rep; Stabilizing vimentin phosphorylation inhibits stem-like cell properties and metastasis of hybrid epithelial/mesenchymal carcinomas; Authors - Nick A Kuburich